About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker TNXP · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Oct 30, 2026A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Dis…
NCT07621237 · Major Depressive Episode (MDE), Major Depressive Disorder (…
TNX-102 SL, Placebo sublingual tablet
TNXP
Tonix Pharmaceuticals, Inc.
Phase 2Recruiting360Feb 2028Registry ↗
Mar 16, 2026A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to…
NCT07473752 · Phase 1 First-in-human Study Involving Healthy Subjects
TNX-1500, Placebo: USP 0.9% sterile saline for injection
TNXP
Tonix Pharmaceuticals, Inc.
Phase 1Completed26Feb 22, 2024Registry ↗
Mar 11, 2026A Single-Dose, Randomized, Open-Label, 2-Way Crossover Study to Evaluate the Dose-Proportionality,…
NCT07464535 · Healthy Subjects (HS)
TNX-102 SL
TNXP
Tonix Pharmaceuticals, Inc.
Phase 1Completed20Apr 30, 2022Registry ↗
Feb 17, 2026A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102…
NCT07413367 · Pharmakokinetic, Open Label
TNX-102 SL Tablet
TNXP
Tonix Pharmaceuticals, Inc.
Phase 1Active, not recruiting50Feb 10, 2026Registry ↗
Jun 24, 2025Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxicat…
NCT06045793 · Cocaine Use, Cocaine Intoxication
TNX-1300 (Injection), Placebo (Injection)
TNXP
Tonix Pharmaceuticals, Inc.
Phase 2Terminated3Apr 21, 2025Registry ↗
Feb 25, 2025A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine
NCT05679908 · Chronic Migraine, Chronic Migraine, Headache
TNX-1900, Placebo Nasal Spray
TNXP
Tonix Pharmaceuticals, Inc.
Phase 2Completed88Oct 8, 2023Registry ↗
Feb 25, 2025Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime…
NCT02829814 · Fibromyalgia, Myofascial Pain Syndromes
TNX-102 SL Tablet, 2.8 mg, Placebo SL Tablet
TNXP
Tonix Pharmaceuticals, Inc.
Phase 3Terminated51Sep 13, 2016Registry ↗
Feb 20, 2025A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
NCT02589275 · Primary Fibromyalgia
TNX-102 SL Tablet 2.8 mg
TNXP
Tonix Pharmaceuticals, Inc.
Phase 3Completed375Sep 28, 2016Registry ↗
Feb 17, 2025Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder…
NCT05686408 · Depression, Depressive Disorder
TNX-601 ER, Placebo
TNXP
Tonix Pharmaceuticals, Inc.
Phase 2Completed132Sep 29, 2023Registry ↗
Feb 7, 2025A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patient…
NCT02436096 · Fibromyalgia, Myofascial Pain Syndromes
TNX-102 SL Tablet, 2.8mg, Placebo SL Tablet
TNXP
Tonix Pharmaceuticals, Inc.
Phase 3Completed519Sep 2016Registry ↗
Feb 6, 2025A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD
NCT03841773 · PTSD
TNX-102 SL, Placebo SL Tablets
TNXP
Tonix Pharmaceuticals, Inc.
Phase 3Terminated192Apr 24, 2020Registry ↗
Feb 6, 202512-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients
NCT03110575 · PTSD
TNX-102 SL
TNXP
Tonix Pharmaceuticals, Inc.
Phase 3Terminated190Jul 27, 2018Registry ↗
Feb 6, 2025Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and R…
NCT02421679 · PTSD
TNX-102 SL
TNXP
Tonix Pharmaceuticals, Inc.
Phase 2Completed159May 26, 2016Registry ↗
Feb 5, 2025A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD
NCT03508700 · PTSD
TNX-102 SL 5.6 mg
TNXP
Tonix Pharmaceuticals, Inc.
Phase 3Completed93Sep 30, 2019Registry ↗
Jan 22, 2025A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibr…
NCT05273749 · Fibromyalgia
TNX-102 SL Tablet, 5.6 mg, Placebo SL Tablet
TNXP
Tonix Pharmaceuticals, Inc.
Phase 3Completed457Nov 14, 2023Registry ↗
Nov 26, 2024A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain…
NCT05472090 · Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19
TNX-102 SL, Placebo SL Tablet
TNXP
Tonix Pharmaceuticals, Inc.
Phase 2Completed63Jul 12, 2023Registry ↗
Nov 6, 2024Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens
NCT05216510 · Detection of Delayed-type Hypersensitivity Reactions to SAR…
TNX-2110, TNX-2120
TNXP
Tonix Pharmaceuticals, Inc.
Phase 1Terminated9Sep 17, 2022Registry ↗
Jun 20, 2024Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditio…
NCT02277704 · PTSD
TNX-102 SL, Placebo
TNXP
Tonix Pharmaceuticals, Inc.
Phase 2Completed245May 2016Registry ↗
May 22, 2024Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD
NCT03062540 · PTSD
TNX-102 SL, Placebo SL Tablet
TNXP
Tonix Pharmaceuticals, Inc.
Phase 3Terminated358Jul 27, 2018Registry ↗
Dec 18, 2023A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia
NCT04508621 · Fibromyalgia
TNX-102 SL, Placebo SL Tablet
TNXP
Tonix Pharmaceuticals, Inc.
Phase 3Completed514Nov 1, 2021Registry ↗
Dec 11, 2023Safety and Efficacy Study of TNX-102 SL in Participants With PTSD
NCT05372887 · PTSD
TNX-102 SL, Placebo
TNXP
Tonix Pharmaceuticals, Inc.
Phase 2Withdrawn0Nov 8, 2022Registry ↗
Aug 8, 2022A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia
NCT04172831 · Fibromyalgia
TNX-102 SL, Placebo SL Tablet
TNXP
Tonix Pharmaceuticals, Inc.
Phase 3Completed503Oct 29, 2020Registry ↗
Jun 29, 2022An Open-Label, Randomized Pilot Study Comparing the Safety of a Single Dose of TNX-1300 to Usual Ca…
NCT04996056 · Cocaine Intoxication
TNX-1300, Usual Care
TNXP
Tonix Pharmaceuticals, Inc.
Phase 2Withdrawn0Jun 16, 2022Registry ↗
Jan 6, 2020Dose-Proportionality and Food Effect Study of TNX-102 SL
NCT04164719 · Healthy Subjects
TNX-102 SL
TNXP
Tonix Pharmaceuticals, Inc.
Phase 1Completed16Dec 24, 2019Registry ↗
Sep 11, 2019A Comparative Bioavailability and Pharmacokinetic Study of TNX-102 2.4 mg and Cyclobenzaprine 5 mg…
NCT01490788 · Healthy
Treatment A, Treatment B
TNXP
Tonix Pharmaceuticals, Inc.
Phase 1Completed30Dec 30, 2011Registry ↗
Jul 11, 2019Bioequivalence Study of TNX-102 SL 2.8 mg Sublingual Tablets From Two Manufacturers.
NCT03168022 · Healthy Adults
Treatment A, Treatment B
TNXP
Tonix Pharmaceuticals, Inc.
Phase 1Completed43Jan 26, 2016Registry ↗
Apr 24, 2018Steady-State Pharmacokinetic Comparison Study of TNX-102 SL 5.6 mg Versus AMRIX® 30 mg ER Capsules
NCT03443960 · Healthy Subjects
TNX-102 SL 5.6 mg, Amrix 30 mg
TNXP
Tonix Pharmaceuticals, Inc.
Phase 1Completed60Apr 9, 2018Registry ↗
Jul 7, 201712-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients
NCT02015234 · Primary Fibromyalgia
TNX-102 SL
TNXP
Tonix Pharmaceuticals, Inc.
Phase 3Completed158Aug 2015Registry ↗
Apr 11, 2017Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache
NCT02423408 · Tension-Type Headache
TNX-201, Placebo
TNXP
Tonix Pharmaceuticals, Inc.
Phase 2Completed165Feb 2016Registry ↗
Dec 23, 2016BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT)
NCT01903265 · Primary Fibromyalgia
TNX-102 SL 2.8mg, Placebo
TNXP
Tonix Pharmaceuticals, Inc.
Phase 2/3Completed205Jul 2014Registry ↗
May 17, 2016Phase 1 Single Ascending Dose Safety Study of TNX-201 Capsules in Healthy Volunteers
NCT02290379 · Healthy
TNX-201 35 mg, TNX-201 70 mg
TNXP
Tonix Pharmaceuticals, Inc.
Phase 1Completed27May 2015Registry ↗

31 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:40 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances